Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism

References

• Medsger TA Jr. Systemic sclerosis (scleroderma), clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. 15th ed. Baltimore: Williams and Wilkins; 2004. p. 1433–64.
   Google Scholar
• Medsger TA Jr, Steen VD. Classification and prognosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Philadelphia: Williams and Wilkins; 1996. p. 51–64.
   Google Scholar
• Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994;103:359–63.
   Google Scholar
• Bazzichi L, Rossi A, Giannaccini G, Betti L, Cercignani G, Giuliano T, Mascia G, et al. Decreased elastase activity in circulat-ing granulocytes of systemic sclerosis patients: a possible pathoge-netic role. Scand J Ftheumatol 2005;34:494–5.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum 1989;32:817–25.
   Google Scholar
• Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: potential role in glomerulosderosis and tubuloin-tersitial fibrosis. Kidney Int 2000;58:1389–99.
   PubMed Web of Science ®Google Scholar
• Shin-wen X, Pennington D, Holmes A, Leask A, Bradham D, Beauchamp JR, et al. Autocrine overexpression of CTGF main-tains fbrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000;259;213–24.
   Google Scholar
• Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 1999;181:153–9.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Nawa K, Ichihara A. Partial purification and charac-terization of hepatocyte growth factor from serum of hepatecto-mized rats. Biochem Biophys Res Commun 1984;122:1450–9.
   Google Scholar
• Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995;345:293–5.
   PubMed Web of Science ®Google Scholar
• Bardelli A, Longati P, Albero D, Goruppi S, Schneider C, Ponzetto C, et al. HGF receptor associates with anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996;15:6205–12.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Matsumoto K, Ichida T, Nakamura T. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem 1995;118:643–9.
   PubMed Web of Science ®Google Scholar
• Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226–30.
   PubMed Web of Science ®Google Scholar
• Inoue T, Okada H, Kobayashi T, Watanabe Y, Kanno Y, Kopp JB, et al. Hepatocyte growth factor counteracts transforming growth factor-I31, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J 2003;17:268–70.
   PubMedGoogle Scholar
• Kawaguchi Y, Harigai M, Hara M, Fukasawa C, Takagi K, Tanaka M, et al. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J Ftheumatol 2002;29:1877–83.
   Google Scholar
• Kawaguchi Y, Harigai M, Fukasawa C, Hara M. Increased levels of hepatocyte growth factor in sera of patients with systemic sclerosis. J Ftheumatol 1999;26:1012–3.
   Google Scholar
• Wu M-H, Yokozeki H, Takagawa S, Yamamoto T, Satoh T, Kaneda Y, et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Therapy 2004;11:170–80.
   Google Scholar
• Jinnin M, Inn H, Mimura Y, Asano Y, Yamane K, Tamaki K. Effects of hepatocyte growth factor on the expression of type IcoHagen and matrix metalloproteinase-1 on normal and sclero-derma dermal fibroblasts. J Invest Dermatol 2005;124;324–30.
   PubMed Web of Science ®Google Scholar
• Subcommittee for Scleroderma Criteria of the American Rheuma-tism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scle-roderma). Arthritis Rheum 1980;23:581–90.
   PubMed Web of Science ®Google Scholar
• LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro. A possible defect in the regulation or activation of the scleroderma fibroblasts. J Chin Invest 1974;54:880–9.
   Google Scholar
• Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T. Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mFtNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990;86: 917–22.
   Google Scholar
• Ozaki I, Zhao G, Mizuta T, Ogawa Y, Hara T, Kajihara S, et al. Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. J Hepatol 2002;36:169–78.
   PubMed Web of Science ®Google Scholar
• Westermarck J, Seth A, Kahari VM. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS tran-scription factors. Oncogene 1997;14: 2651–60.
   Google Scholar
• Ozaki I, Mizuta T, Zhao G, Zhang H, Yoshimura T, Kawazoe S, et al. Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a tran-scription factor Ets-1. Hepatol Res 2003;27:289–301.
   PubMed Web of Science ®Google Scholar
• Inn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signalling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with in-creased expression of transforming growth factor beta receptors. Arthritis Rheum 2001;44:474–80.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Dudhia J, Bird JL, Bayliss MT. Age-related effects of TGF-beta on proteoglycan synthesis in equine articular cartilage. Biochem Biophys Res Commun 2000;274:467–71.
   PubMed Web of Science ®Google Scholar
• Blaney Davidson EN, Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduced transforming growth factor-beta signalling in cartilage of old mice: role in impaired repair capacity. Arthritis Res Ther 2005;7:1338–47.
   Google Scholar
• Takehara K. Pathogenesis of systemic sclerosis. J Ftheumatol 2003;30:755–9.
   Web of Science ®Google Scholar
• Chujo S, Shirasaki F, Kawara S, Inagaki Y, Kinbara T, Inaoki M, et al. Connective tissue growth factor caused persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 2005;203:447–56.
   PubMed Web of Science ®Google Scholar
• Van Beek JP, Kennedy L, Rocket JS, Bernier SM, Leask A. The induction of CCN2 by TGFbetal involves Ets-1. Arthritis Res Ther 2006;8:R36.
   Google Scholar
• Yang J, Dai C, Liu Y. Hepatocyte growth factor suppressed renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 2003;163:621–32.
   Google Scholar
• Gillery P, Serpier H, Polette M, Belton G, Clavel C, Wegrowski Y, et al. Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. Eur J Cell Biol 1992;57:244–53.
   PubMed Web of Science ®Google Scholar
• Duncan MR, Berman B. Stimulation of collagen and glycosami-noglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686–92.
   PubMed Web of Science ®Google Scholar
• Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with sclero-derma. J Ftheumatol 1992;19:1207–11.
   Google Scholar
• Parr C, Jiang WG. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 2001;19:857–63.
   PubMed Web of Science ®Google Scholar
• Arakaki N, Kajihara T, Arakaki R, Ohnishi T, Kazi JA, Nakashima H. et al. Involvement of oxidative stress in tumor cyto-toxic activity of hepatocyte growth factor/scatter factor. J Biol Chem 1999;274:13541–6.
   PubMed Web of Science ®Google Scholar
• Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G, LaRochelle WJ. Hepatocyte growth factor/Scatter factor over-expression induces growth, abnormal development, and tumor for-mation in transgenic mouse livers. Cell Growth Differ 1996;7: 1513–23.
   PubMedGoogle Scholar